Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records

[1] Bradley R(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352

[2] Braybrooke J(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[3] Gray R(2022)Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Lancet Oncol 23 382-392

[4] Hills RK(2019)Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain Breast Cancer Res Treat 99 1763-1768

[5] Liu Z(2008)Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 108 1515-1524

[6] Pan H(2013)Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality Br J Cancer 126 529-537

[7] Peto R(2011)Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer Breast Cancer Res Treat 33 2262-2269

[8] Dodwell D(2015)Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer J Clin Oncol 134 459-478

[9] McGale P(2012)Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review Breast Cancer Res Treat 36 45-54

[10] Taylor C(2014)Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer Int J Clin Pharm 34 2452-2459

[1] Bradley R(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352

[2] Braybrooke J(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[3] Gray R(2022)Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Lancet Oncol 23 382-392

[4] Hills RK(2019)Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain Breast Cancer Res Treat 99 1763-1768

[5] Liu Z(2008)Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 108 1515-1524

[6] Pan H(2013)Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality Br J Cancer 126 529-537

[7] Peto R(2011)Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer Breast Cancer Res Treat 33 2262-2269

[8] Dodwell D(2015)Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer J Clin Oncol 134 459-478

[9] McGale P(2012)Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review Breast Cancer Res Treat 36 45-54

[10] Taylor C(2014)Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer Int J Clin Pharm 34 2452-2459